Final Revisions Should Ease Global Use Of EU GMP Annex I Sterile Drugs Guidance, Associations Say
Executive Summary
Inter-associations working group suggests changes to the EU GMP Annex I revision to make it easier to understand by health authorities worldwide; the groups point out that the annex will be used globally and not just in Europe.
You may also be interested in...
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
Industry Makes Final Arguments Against PUPSIT Before EC Decides On EU GMP Annex 1 Revision
Despite improvements, latest EU GMP Annex 1 revision draws another round of objections to PUPSIT filter testing provision.
The Quality Lowdown: Coronavirus Prompts EU To Extend Comment Deadline For Annex 1
Industry gets time to craft more objections to EU GMP PUPSIT provision, excipient data integrity advice offered, FDA MAPPs revised, US hits Health Solutions while EU hits Dishman Carbogen, and 11 added to FDA drug GMP import alert.